Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-07-05
2011-07-05
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S545000
Reexamination Certificate
active
07973031
ABSTRACT:
The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3 receptor tyrosine kinase activity.
REFERENCES:
patent: 5093330 (1992-03-01), Caravatti et al.
patent: 5545636 (1996-08-01), Heath, Jr. et al.
patent: 5658898 (1997-08-01), Weder et al.
patent: 5726164 (1998-03-01), Weder et al.
patent: 0 296 110 (1988-12-01), None
patent: 0 383 919 (1990-08-01), None
patent: 0 397 060 (1990-11-01), None
patent: 0 575 955 (1993-12-01), None
patent: 0 624 586 (1994-11-01), None
patent: 0 711 556 (1996-05-01), None
patent: 0 711 557 (1996-05-01), None
patent: 0 733 358 (1996-09-01), None
patent: 0 733 372 (1996-09-01), None
patent: 0 990 442 (2000-04-01), None
patent: 1 109 020 (2001-06-01), None
patent: 225297 (2006-09-01), None
patent: 91 09034 (1991-06-01), None
patent: WO 93/07153 (1993-04-01), None
patent: WO 9402486 (1994-03-01), None
patent: WO 95/32976 (1995-12-01), None
patent: WO 98/07415 (1998-02-01), None
patent: 99 02532 (1999-01-01), None
patent: WO 00/48571 (2000-08-01), None
Sedlak et al., Protein Kinase Inhibitor-Induced Alterations of Drug Uptake, Cell Cycle and Surface Antigen Expression in Human Multidrug-Resistant (Pgp and MRP) Promyelocytic Leukemia HL-60 Cells, Leukemia Research, vol. 21, No. 5, pp. 449-458, 1997.
Millward et al., The Multikinase inhibitor midostaurin (PKC412A) Lacks Activity in Metastatic Melanoma: A Phase IIA Clinical and Biologic Study, British Journal of Cancer, vol. 95, pp. 829-834, 2006.
Heidel et al., Clinical Resistance to the Kinase Inhibitor PKC412 in Acute Myeloid Leukemia by Mutation of Asn-676 in the FLT3 Tyrosine Kinase Domain, Blood, vol. 107, No. 1, pp. 293-300, Jan. 1, 2006.
Weisberg et al., Inhibition of Mutant FLT3 Receptors in Leukemia Cells by the Small Molecule Tyrosine Kinase Inhibitor PKC412, Cancer Cell, vol. 1, No. 5, 2002, pp. 433-443.
Meyer et al., “A derivative of Staurosporine (CGP 41 251) shows selectively for protein kinase C inhibition and in vitro anti-proliferative as well as in vito anti-tumor activity”, Int. J. Cancer, vol. 43, 851-856, 1989 pp. 851, 854 and 855.
Fallon, “Staurosporine inhibits a tyrosine protein kinase in human hepatoma cell membrances,” Biochem, Biophys. Res. Commun., vol. 170, No. 3, 1191-1196, 1990.
Secrist et al, “Preferential inhibition of the platelet-derived growth factor receptor tyrosine kinase by staurosporine”, J. Biol. Chem., vol. 265, No. 33, 20394-20400, 1990.
Meshinchi, et al., “Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia”, Blood, vol. 97, No. 1, 89-94, 2001.
Lisovsky et al, “Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax”, Blood, vol. 88, No. 10, 3987-3997, 1996.
Grosis, Konstantina, “Midostaurin Novartis AG”, Curr. Opin. Oncol. Endocr. Metab. Inves., (2002), vol. 2, pp. 92-103.
Griffin James Douglas
Manley Paul William
Coleman Brenda
Dana-Farber Cancer Institute Inc
Dohmann George R.
Konzak Kristin E.
McNally Lydia T.
LandOfFree
Staurosporine derivatives as inhibitors of FLT3 receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Staurosporine derivatives as inhibitors of FLT3 receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Staurosporine derivatives as inhibitors of FLT3 receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2720373